Ross Ferguson

Ross Ferguson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ross Ferguson has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Ahad Abdul Rahim

    School of Pharmacy, University College London, London WC1N 1AX, UK

    1 shared publication
  • Gabriele Lignani

    Research Department of Epilepsy, UCL Queen Square Institute of Neurology, University College London

    1 shared publication
  • Haiyan Zhou

    Genetics and Genomic Medicine Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK

    1 shared publication
  • Kristian Aquilina

    Department of Neurosurgery, Great Ormond Street Hospital for Children, London, UK

    1 shared publication
  • Lucy Coupland

    Huntington’s Disease Centre, Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, University College London

    1 shared publication
  • Manju A. Kurian

    Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom; Department of Neurology, Great Ormond Street Hospital for Children, London, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    Genetic therapies for neurological diseases

    by Ahad A. Rahim, Manju A. Kurian, Haiyan Zhou, Ross Ferguson, Sarah J. Tabrizi, Gabriele Lignani, Kristian Aquilina, Simon N. Waddington


  • Open Access

    Targeted Deletion in the Basal Body Protein Talpid3 Leads to Loss of Primary Cilia in Embryonic Stem Cells and Defective Lineage-Specific Differentiation

    by Ross Ferguson, Vasanta Subramanian

    Talpid3 is a basal body protein required for the formation of primary cilia, an organelle involved in signal transduction. Here, we asked if Talpid3 has a role in the regulation of differentiation and/or self-renewal of ES cells and whether cells lacking cilia due to a deletion in Talpid3 can be reprogrammed to induced pluripotent stem (iPS) cells. We show that mouse embryonic limb fibroblasts which lack primary cilia with a targeted deletion in the Talpid3 (Ta3) gene can be efficiently reprogrammed to iPS cells. Furthermore, vector-free Ta3−/− iPS cells retain ES cell features and are able to self-renew. However, both Ta3−/− iPS and ES cells are unable to form visceral endoderm and differentiate poorly into neurons. The observed defects are not a consequence of reprogramming since Ta3−/− ES cells also exhibit this phenotype. Thus, Talpid3 and primary cilia are required for some differentiation events but appear to be dispensable for stem cell self-renewal and reprogramming.

  • Open Access

    Therapeutic validation of MMR-associated genetic modifiers in a human ex vivo model of Huntington’s disease

    by Ross Ferguson, Robert Goold, Lucy Coupland, Michael Flower, Sarah J Tabrizi

    The pathological huntingtin ( HTT ) trinucleotide repeat underlying Huntington’s disease (HD) continues to expand throughout life. Repeat length correlates both with earlier age at onset (AaO) and faster progression, making slowing its expansion an attractive therapeutic approach. Genome-wide association studies have identified candidate variants associated with altered AaO and progression, with many found in DNA mismatch repair (MMR) associated genes. We examine whether lowering expression of these genes affects the rate of somatic expansion in human ex vivo models using HD iPSCs and HD iPSC-derived striatal neurons. We have generated a stable CRISPR interference HD iPSC line in which we can specifically and efficiently lower gene expression from a donor carrying over 125 CAG repeats. Lowering expression of each member of the MMR complexes MutS (MSH2, MSH3 & MSH6), MutL (MLH1, PMS1, PMS2 & MLH3) and LIG1 resulted in characteristic MMR deficiencies. Reduced MSH2, MSH3 and MLH1 slowed repeat expansion to the largest degree, while lowering either PMS1, PMS2 and MLH3 slowed it to a lesser degree. These effects were recapitulated in iPSC derived striatal cultures where MutL factor expression was lowered. Here, reducing the expression of MMR factors by CRISPRi to levels typically reached by current therapeutics effectively slows the pathogenic expansion of the HTT CAG repeat tract. We highlight members of the MutL family as potential therapeutic targets to slow repeat expansion with the aim to delay onset and progression of HD, and potentially other repeat expansion disorders exhibiting somatic instability. GRAPHICAL